Overview

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Assess whether the combination of ABT-888 with FOLFIRI has activity in subjects with gastric cancer.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Veliparib